Golimumab Benefits Hold Up Over Time in RA

Posted in News, World

– Negligible radiographic progression seen through 2 years of treatment.

Clinical responses to intravenous golimumab (Simponi Aria) among patients with rheumatoid arthritis persisted through 2 years of treatment, a study known as GO-FURTHER found.

Among 486 patients who completed 2 years of treatment with intravenous golimumab plus methotrexate, a 20% improvement according to the criteria of the American College of Rheumatology (ACR20) was seen in 68.1%, according to Clifton O. Bingham III, MD, of Johns Hopkins University, and colleagues.

• Continue Reading

TrialReach Raises $13.5M Series B To Match Patients To Clinical Trials

Posted in News, World

TrialReach is an interesting startup on a number of fronts. Firstly, the company is based in London but does most of its business in the “fast-moving” U.S. healthcare market. Secondly, and more significantly, it’s using technology to solve a very human problem and one of the biggest obstacles in medical research: matching the right patients with the right clinical trials, which in turn should help speed up the development of new treatments and ultimately save lives.

• Continue Reading